Answers are grounded in this paper and cite their sources.
Population pharmacokinetic modeling demonstrates a weight-band dosing regimen for vosoritide in achondroplasia, suggesting effective exposure across pediatric body weights.
Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short stature, that has been shown to be well tolerated and effective in increasing linear growth. This study aimed to develop a population pharmacokinetic (PPK) model to characterize pharmacokinetics (PK) of vosoritide and establish a weight-band dosing regimen.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: